Shares of ESSA Pharma (CVE EPI) opened at C$0.30 on Thursday. ESSA Pharma has a 12 month low of C$0.22 and a 12 month high of C$4.60. The stock has a market cap of $8.72 and a PE ratio of -1.43.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.